News
Press Releases
2015/12/07
Dr. Ge Li Receives Executive of the Year Award from SCRIP
SHANGHAI, Dec. 7, 2015 -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, today announced that Dr. Ge Li, WuXi's Chairman and CEO, was named Executive of the Year at the 11th annual SCRIP Awards on December 2 in London. Established by SCRIP Intelligence, a leading industry news and strategic analysis firm covering the global pharmaceutical and biotech industry, the annual SCRIP Awards recognize the industry's highest achievements by both companies and individuals across the value chain.
Read more2015/11/11
WuXi PharmaTech and Lilly Announce Strategic Collaboration to Develop Novel Therapeutic in China
SHANGHAI, November 11, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX) and Eli Lilly and Company (NYSE: LLY) today announced that they have entered into a strategic collaboration to develop, manufacture and commercialize a novel small molecule in China.
Read more2015/11/06
WuXi PharmaTech Congratulates Novira Therapeutics
SHANGHAI, November 6, 2015 /PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, congratulates our partner and WuXi Venture Fund portfolio company Novira Therapeutics for its agreement to be acquired by Johnson and Johnson.
Read more2015/11/03
WuXi PharmaTech Announces Third-Quarter 2015 Results
WuXi PharmaTech (Cayman) Inc. ("WuXi" or the "Company") (NYSE: WX) announces the following financial information for the third quarter ended September 30, 2015.
Read more2015/10/30
Gilead Sciences and WuXi PharmaTech Announce Collaboration for a Dedicated Analytical and Stability Testing Facility
SHANGHAI, Oct. 30, 2015 /PRNewswire/ -- Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
Read more